Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E.

Clin Cancer Res. 2008 Mar 1;14(5):1455-63. doi: 10.1158/1078-0432.CCR-07-0371.

2.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

3.

Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.

Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, Kern SE, Iacobuzio-Donahue CA.

Clin Cancer Res. 2008 Jan 15;14(2):412-8. doi: 10.1158/1078-0432.CCR-07-0487.

4.
5.

Differentiation plasticity regulated by TGF-beta family proteins in development and disease.

Derynck R, Akhurst RJ.

Nat Cell Biol. 2007 Sep;9(9):1000-4.

PMID:
17762890
6.

National failure to operate on early stage pancreatic cancer.

Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS.

Ann Surg. 2007 Aug;246(2):173-80.

7.

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J.

Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10.

PMID:
17600091
8.

Surgical therapy for colorectal metastases to the liver.

Pawlik TM, Choti MA.

J Gastrointest Surg. 2007 Aug;11(8):1057-77. Review.

PMID:
17530336
9.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

PMID:
17452677
10.

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.

Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A.

Cancer Res. 2007 Mar 1;67(5):2187-96.

11.

Identification of pancreatic cancer stem cells.

Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM.

Cancer Res. 2007 Feb 1;67(3):1030-7.

12.

Cancer statistics, 2007.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.

CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.

PMID:
17237035
13.

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA.

Genes Dev. 2006 Nov 15;20(22):3130-46.

14.

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ.

J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1.

PMID:
17114007
15.

Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification.

Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, Nagawa H.

Br J Cancer. 2006 Dec 4;95(11):1562-7. Epub 2006 Nov 7.

16.

Dynamics of metastasis suppressor gene inactivation.

Michor F, Iwasa Y.

J Theor Biol. 2006 Aug 7;241(3):676-89. Epub 2006 Feb 23.

PMID:
16497335
17.

The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.

Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P.

Cancer Res. 2006 Feb 15;66(4):2202-9.

18.

TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN.

Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A.

J Cell Sci. 2005 Oct 15;118(Pt 20):4901-12.

19.

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL, Massagué J.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14. Epub 2005 Sep 19. Erratum in: Proc Natl Acad Sci U S A. 2006 May 30;103(22):8570.

20.

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA.

Cancer Cell. 2005 May;7(5):469-83.

Supplemental Content

Support Center